Correlation between acid-suppressive medications and risk of osteoporosis-related fractures: a meta-analysis

doi:10.3969/j.issn.2095-4344.2014.33.027

Abstract

Abstract:

BACKGROUND: Whether a long-term use of acid-suppressive medication for over 3 years can increase the risk of fractures, remains controversial.
OBJECTIVE: To systematically review the effect of acid-suppressive medication on fracture risk.
METHODS: Clinical trials about the relationship of acid-suppressive medication use and risk of osteoporosis-related fractures were searched in MEDLINE, Cochrane Library, EMbase, and CNKI database. We also manually searched some published and unpublished references. Study selection and assessment, data collection and analyses were undertaken by two reviewers independently. The Cochrane Collaboration’s RevMan 5.0 software was used for data analyses.
RESULTS AND CONCLUSION: After a comprehensive search, 11 original clinical trials were included in this meta-analysis, including 3 nested case-control studies, 5 case-control studies, and 3 cohort studies. Patients with fractures were more likely than controls to have previously received supply of proton pump inhibitors [odds ratio (OR)=1.29, 95% confidence interval (CI) (1.18-1.41), P < 0.001]. The meta-analysis did not find a significant difference in the patients who received H2 receptor antagonists [OR=1.10, 95%CI (0.99-1.23), P=0.34]. A long-term use of proton pump inhibitors is associated with an increased risk of fracture in elderly persons already at a risk for osteoporosis.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: acid-suppressive medication, fracture risk, meta-analysis

CLC Number:

R318

Dong Rui, Xiang Zheng, Lin Han-sheng. Correlation between acid-suppressive medications and risk of osteoporosis-related fractures: a meta-analysis[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(33): 5402-5406.

Figures/Tables 3

References

[1]IMS Health. IMS Health; 2005. Leading Therapy Classes by Pharmaceutical Sales.
[2]朱琳,胡予.有关质子泵抑制剂的安全性评价[J].中华消化杂志, 2013,33(10):712-714.
[3]Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int.2008;83(4):251-259.
[4]Roux C, Briot K, Gossec L, et al.Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int.2009;84(1):13-19.
[5]Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med.2010;170(9):765-771.
[6]Targownik LE, Lix LM, Metge CJ,et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319-326.
[7]Vestergaard P, Rejnmark L, Mosekilde L.Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int.2006;79(2):76-83.
[8]Grisso JA, Kelsey JL, O’Brien LA, et al. Hip Fracture Study Group. Risk factors for hip fracture in men. Am J Epidemiol. 1997;145(9):786-793.
[9]Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011; 22(3):903-910.
[10]Chiu HF, Huang YW, Chang CC,et al. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2010;19(11):1131-1136.
[11]Yang YX, Lewis JD, Epstein S,et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296 (24):2947-2953.
[12]Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951-959.
[13]Corley DA, Kubo A, Zhao W,et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010; 139(1):93-101.
[14]Cea-Soriano L1, Johansson S, García Rodríguez LA. Risk factors for falls with use of acid-suppressive drugs. Epidemiology. 2013;24(4):600-607.
[15]黄洪新，徐道华.细胞因子与骨质疏松症[J].国际骨科学杂志，2011,32(5):307-309.
[16]Familiar C1, Antón T, Moraga I,et al. About a case of multiple endocrine neoplasia type 1. Review of some clinical manifestations and treatment controversies. Endocrinol Nutr. 2011;58(2):84-89.
[17]Sheikh MS, Santa Ana CA, Nicar MJ, et al. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med.1987;317:532-536.
[18]Chonan O, Takahashi R, Yasui H,et al. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo). 1998;44:473-481.
[19]Chonan O, Takahashi R, Yasui H,et al. Effect of L-lactic acid on the absorption of calcium in gastrectomized rats. J Nutr Sci Vitaminol (Tokyo). 1998;44:869-875.
[20]Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995; 14:364-368.
[21]O’Connell MB, Madden DM, Murray AM,et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118: 778-781.
[22]Farina C, Gagliardi S. Selective inhibition of osteoclast vacuolar H(+)-ATPase. Curr Pharm Des. 2002;8:2033-2048.
[23]Cea Soriano L1, Ruigómez A, Johansson S,et al.Study of the Association Between Hip Fracture and Acid-Suppressive Drug Use in a UK Primary Care Setting.Pharmacotherapy. Pharmacotherapy. 2014;34(6):570-581.
[24]Hasanin AH.Impact of omeprazole on bone remodeling in normal and ovariectomized Wistar rats. Eur Rev Med Pharmacol Sci. 2014;18(13):1948-1956.
[25]Costa-Rodrigues J, Reis S, Teixeira S, et al. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J. 2013; 280(20):5052-5064.
[26]Lee J, Youn K, Choi NK, et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol. 2013; 48(9): 1016-1022.
[27]Yang YX. Chronic proton pump inihibitor therapy and calcium metabolism. Curr Gastroenterol Rep. 2012;14(6):473-479.
[28]Moberg LM, Nilsson PM, Samsioe G，et al. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas. 2014;78(4):310-315.
[29]Wen Z, Li X, Lu Q, Brunson J,et al. Health related quality of life in patients with chronic gastritis and peptic ulcer and factors with impact: a longitudinal study. BMC Gastroenterol. 2014;14(1):149.
[30]Qin F, Liu JY, Yuan JH. Chaihu-Shugan-San, an oriental herbal preparation, for the treatment of chronic gastritis: a meta-analysis of randomized controlled trials. J Ethnopharmacol. 2013 Mar 27;146(2):433-439.
[31]Nagaoka H1, Terajima M, Yamada S, et al. Alfacalcidol enhances collagen quality in ovariectomized rat bones. J Orthop Res. 2014 Aug;32(8):1030-1036.
[32]Lewis JR1, Barre D, Zhu K,et al. Long-Term Proton Pump Inhibitor Therapy and Falls and Fractures in Elderly Women: A Prospective Cohort Study. J Bone Miner Res. 2014 May 13. doi: 10.1002/jbmr.2279.
[33]Maggio M, Lauretani F, Ceda GP, et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013;57(2):437-442.